-
EP3430907
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3430907
| EP3430907 - TREATMENT OF BREAST CANCER [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 13.12.2019 Database last updated on 05.07.2024 | |
| Former | The application has been published Status updated on 21.12.2018 | Most recent event Tooltip | 13.12.2019 | Application deemed to be withdrawn | published on 15.01.2020 [2020/03] | Applicant(s) | For all designated states Medivation Prostate Therapeutics LLC 525 Market Street 36th Floor San Francisco, CA 94105 / US | For all designated states The Regents of the University of Colorado, a body corporate 1800 Grant Street, 8th Floor Denver, CO 80203 / US | [2019/04] | Inventor(s) | 01 /
PROTTER, Andrew c/o Medivation Prostate Therapeutics LLC 201 Spear Street San Francisco, CA California 94105 / US | 02 /
RICHER, Jennifer c/o Technology Transfer Office University of CO 12635 E. Montview Blvd. Suite 350 Aurora, CO Colorado 80045 / US | 03 /
COCHRANE, Dawn c/o Technology Transfer Office University of CO 12635 E. Montview Blvd. Suite 350 Aurora, CO Colorado 80045 / US | [2019/04] | Representative(s) | Wilson, Justin Scott Withers & Rogers LLP 2 London Bridge London SE1 9RA / GB | [N/P] |
| Former [2019/04] | Wilson, Justin Scott Withers & Rogers LLP 4 More London Riverside London SE1 2AU / GB | Application number, filing date | 18190012.7 | 27.07.2012 | [2019/04] | Priority number, date | US201161513361P | 29.07.2011 Original published format: US 201161513361 P | [2019/04] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3430907 | Date: | 23.01.2019 | Language: | EN | [2019/04] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 20.12.2018 | Classification | IPC: | A01N47/28, A61K31/17, A61P35/00, A61K31/4166, A61K31/4184 | [2019/04] | CPC: |
A61K31/4184 (EP,US);
A61K31/4166 (EP,US);
A61P35/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/04] | Title | German: | BEHANDLUNG VON BRUSTKREBS | [2019/04] | English: | TREATMENT OF BREAST CANCER | [2019/04] | French: | TRAITEMENT DU CANCER DU SEIN | [2019/04] | Examination procedure | 24.07.2019 | Application deemed to be withdrawn, date of legal effect [2020/03] | 21.08.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2020/03] | Parent application(s) Tooltip | EP12846720.6 / EP2739153 | Divisional application(s) | EP19187649.9 / EP3610731 | EP20191500.6 / EP3791724 | Fees paid | Renewal fee | 21.08.2018 | Renewal fee patent year 03 | 21.08.2018 | Renewal fee patent year 04 | 21.08.2018 | Renewal fee patent year 05 | 21.08.2018 | Renewal fee patent year 06 | 21.08.2018 | Renewal fee patent year 07 | 09.07.2019 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]US2010172975 (SAWYERS CHARLES L [US], et al) [Y] 1-12 * abstract * * claim - * * paragraphs [0077] , [0335] , [0365] , [0367] , [0370] , [4371] - [0373] - [0007] *; | [YD]US2009111864 (JUNG MICHAEL E [US], et al) [YD] 1-12 * abstract * * paragraphs [0103] , [0121] , [0143] * * claim - *; | [Y]WO2007126765 (UNIV CALIFORNIA [US], et al) [Y] 1-12 * abstract * * claim - *; | [YD]WO2010118354 (MEDIVATION PROSTATE THERAPEUTI [US], et al) [YD] 1-12 * abstract * * claim - *; | [YD]WO2011044327 (MEDIVATION PROSTATE THERAPEUTICS INC [US], et al) [YD] 1-12 * abstract * * claim - *; | [YD]WO2010099238 (MEDIVATION PROSTATE THERAPEUTI [US], et al) [YD] 1-12 * abstract * * claim - *; | [Y] - LEHMANN B D ET AL, "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, (20110701), vol. 121, no. 7, doi:10.1172/JCI45014, ISSN 0021-9738, pages 2750 - 2767, XP002696927 [Y] 1-12 * abstract * * page 2758; figure 5 * * page 2760; figure 7 * * page 2762, column l, paragraph 3 * * page 2762, column r, paragraph last - page 2761, column l, paragraph 2 * * page 2764, column l, paragraph last - column r, paragraph 1 * DOI: http://dx.doi.org/10.1172/JCI45014 | [Y] - SANTANA-DAVILA RAFAEL ET AL, "Treatment options for patients with triple-negative breast cancer", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, (20101027), vol. 3, no. 1, doi:10.1186/1756-8722-3-42, ISSN 1756-8722, page 42, XP021083367 [Y] 1-12 * abstract * * page 48, column r, paragraph 3 * DOI: http://dx.doi.org/10.1186/1756-8722-3-42 | [Y] - FRANCESCA DE AMICIS ET AL, "Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, (20090617), vol. 121, no. 1, ISSN 1573-7217, pages 1 - 11, XP019787451 [Y] 1-12 * abstract * DOI: http://dx.doi.org/10.1007/s10549-009-0436-8 | [Y] - JESSICA L L ROBINSON ET AL, "Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1", THE EMBO JOURNAL, (20110624), vol. 31, no. 6, doi:10.1038/emboj.2012.59, ISSN 0261-4189, pages 1617 - 1617, XP055164145 [Y] 1-12 * abstract * * page 3020; figure 1 * * page 3020, column r, line 8 - page 3021, column l, paragraph 1 * DOI: http://dx.doi.org/10.1038/emboj.2012.59 | [Y] - MIN NI ET AL, "Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer", CANCER CELL, CELL PRESS, US, vol. 20, no. 1, doi:10.1016/J.CCR.2011.05.026, ISSN 1535-6108, (20110527), pages 119 - 131, (20110608), XP028379886 [Y] 1-12 * abstract * * page 128, column l, paragraph last - page 129, column l, paragraph 1 * * page 128; figure 8 * DOI: http://dx.doi.org/10.1016/j.ccr.2011.05.026 | [Y] - TISHEEKA R GRAHAM ET AL, "Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, (20091118), vol. 123, no. 1, ISSN 1573-7217, pages 139 - 147, XP019814417 [Y] 1-12 * abstract * * page 143, column r, line 4 - page 144, column r, paragraph 1 * * page 145; figure 5 * DOI: http://dx.doi.org/10.1007/s10549-009-0623-7 | [Y] - A S DOANE ET AL, "An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen", ONCOGENE, (20060220), vol. 25, no. 28, doi:10.1038/sj.onc.1209415, ISSN 0950-9232, pages 3994 - 4008, XP055164285 [Y] 1-12 * abstract * * page 4001, column l, paragraph 2 - page 4002, column r, paragraph 2 * DOI: http://dx.doi.org/10.1038/sj.onc.1209415 | [T] - DAWN R COCHRANE ET AL, "Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, (20140122), vol. 16, no. 1, doi:10.1186/BCR3599, ISSN 1465-5411, page R7, XP021177323 [T] 1-12 * the whole document * DOI: http://dx.doi.org/10.1186/bcr3599 | by applicant | US7709517 | US2009111864 | US2011003839 | WO2010118354 | WO2011044327 | WO2010099238 | US4608392 | US4992478 | US4559157 | US4820508 | US4938949 | - BERGE et al., "Pharmaceutical Salts", J. Pharm. Sci., (19770100), vol. 66, no. 1, doi:doi:10.1002/jps.2600660104, page l-19, XP002675560 DOI: http://dx.doi.org/10.1002/jps.2600660104 | - CUMMINGS et al., JAMA, (20020000), vol. 287, pages 216 - 20 |